Concepts (258)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Injuries | 13 | 2024 | 121 | 5.230 |
Why?
|
| Brain Concussion | 6 | 2024 | 29 | 3.840 |
Why?
|
| Neurodegenerative Diseases | 3 | 2022 | 131 | 1.690 |
Why?
|
| Blast Injuries | 2 | 2023 | 4 | 1.090 |
Why?
|
| Glycomics | 2 | 2022 | 7 | 1.030 |
Why?
|
| Olfactory Receptor Neurons | 1 | 2024 | 28 | 0.930 |
Why?
|
| Microglia | 3 | 2023 | 166 | 0.920 |
Why?
|
| Receptors, Odorant | 1 | 2024 | 42 | 0.910 |
Why?
|
| Proteomics | 11 | 2023 | 325 | 0.890 |
Why?
|
| Refugees | 1 | 2023 | 19 | 0.870 |
Why?
|
| Tinnitus | 1 | 2022 | 3 | 0.850 |
Why?
|
| Craniocerebral Trauma | 1 | 2022 | 19 | 0.840 |
Why?
|
| Epilepsy | 1 | 2022 | 43 | 0.820 |
Why?
|
| Nervous System Diseases | 1 | 2022 | 71 | 0.800 |
Why?
|
| Central Nervous System Diseases | 1 | 2022 | 29 | 0.800 |
Why?
|
| Humans | 48 | 2024 | 37093 | 0.790 |
Why?
|
| Biosensing Techniques | 1 | 2022 | 86 | 0.750 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2023 | 389 | 0.720 |
Why?
|
| Methamphetamine | 1 | 2021 | 159 | 0.680 |
Why?
|
| Animals | 21 | 2024 | 15081 | 0.680 |
Why?
|
| Foramen Magnum | 3 | 2022 | 3 | 0.640 |
Why?
|
| Vietnam | 3 | 2022 | 50 | 0.630 |
Why?
|
| Rats | 11 | 2023 | 3483 | 0.610 |
Why?
|
| Proteome | 3 | 2023 | 144 | 0.570 |
Why?
|
| Brain | 6 | 2023 | 1346 | 0.540 |
Why?
|
| Ubiquitin Thiolesterase | 3 | 2024 | 52 | 0.500 |
Why?
|
| Mice, Inbred C57BL | 4 | 2022 | 1609 | 0.470 |
Why?
|
| Narcolepsy | 2 | 2023 | 2 | 0.460 |
Why?
|
| Tauopathies | 2 | 2024 | 20 | 0.460 |
Why?
|
| Glial Fibrillary Acidic Protein | 5 | 2024 | 70 | 0.460 |
Why?
|
| Vietnam Conflict | 2 | 2022 | 3 | 0.430 |
Why?
|
| Gene Expression Profiling | 4 | 2024 | 626 | 0.420 |
Why?
|
| Astrocytes | 3 | 2023 | 255 | 0.420 |
Why?
|
| Glioblastoma | 2 | 2023 | 55 | 0.410 |
Why?
|
| Mice | 7 | 2023 | 5913 | 0.390 |
Why?
|
| Alzheimer Disease | 3 | 2024 | 905 | 0.380 |
Why?
|
| Antioxidants | 3 | 2023 | 416 | 0.360 |
Why?
|
| Disease Models, Animal | 4 | 2023 | 1371 | 0.350 |
Why?
|
| Inflammation | 3 | 2023 | 618 | 0.340 |
Why?
|
| MicroRNAs | 2 | 2024 | 426 | 0.300 |
Why?
|
| Aptamers, Nucleotide | 2 | 2024 | 31 | 0.290 |
Why?
|
| Colorectal Neoplasms | 2 | 2023 | 441 | 0.290 |
Why?
|
| Glycopeptides | 2 | 2023 | 12 | 0.280 |
Why?
|
| Lebanon | 2 | 2023 | 6 | 0.270 |
Why?
|
| tau Proteins | 2 | 2024 | 167 | 0.270 |
Why?
|
| Reactive Oxygen Species | 3 | 2023 | 461 | 0.260 |
Why?
|
| Point-of-Care Systems | 2 | 2022 | 27 | 0.250 |
Why?
|
| Male | 12 | 2024 | 20025 | 0.250 |
Why?
|
| Antineoplastic Agents | 2 | 2022 | 803 | 0.240 |
Why?
|
| Neurofilament Proteins | 1 | 2024 | 29 | 0.240 |
Why?
|
| Maze Learning | 2 | 2021 | 105 | 0.240 |
Why?
|
| Hematologic Tests | 1 | 2024 | 7 | 0.240 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2024 | 21 | 0.240 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2023 | 3 | 0.230 |
Why?
|
| Neurosciences | 1 | 2024 | 28 | 0.230 |
Why?
|
| Adipokines | 1 | 2023 | 24 | 0.230 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2024 | 47 | 0.230 |
Why?
|
| Status Epilepticus | 1 | 2023 | 12 | 0.230 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2023 | 35 | 0.230 |
Why?
|
| Satureja | 1 | 2023 | 1 | 0.230 |
Why?
|
| Plague | 1 | 2023 | 25 | 0.220 |
Why?
|
| Syria | 1 | 2023 | 5 | 0.220 |
Why?
|
| Brain Edema | 1 | 2023 | 63 | 0.220 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 197 | 0.220 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2023 | 29 | 0.220 |
Why?
|
| Oils, Volatile | 1 | 2023 | 13 | 0.220 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2022 | 10 | 0.220 |
Why?
|
| Trauma Centers | 1 | 2023 | 79 | 0.220 |
Why?
|
| Neurons | 4 | 2024 | 1175 | 0.220 |
Why?
|
| Fluorouracil | 1 | 2023 | 34 | 0.220 |
Why?
|
| Bupropion | 1 | 2022 | 12 | 0.220 |
Why?
|
| Encephalitis | 1 | 2023 | 42 | 0.210 |
Why?
|
| Unconsciousness | 1 | 2022 | 4 | 0.210 |
Why?
|
| Carbohydrates | 1 | 2022 | 29 | 0.210 |
Why?
|
| Gasoline | 1 | 2022 | 2 | 0.210 |
Why?
|
| Atherosclerosis | 1 | 2023 | 134 | 0.210 |
Why?
|
| Ubiquinone | 1 | 2022 | 22 | 0.200 |
Why?
|
| Schizophrenia | 1 | 2022 | 76 | 0.200 |
Why?
|
| RNA | 1 | 2024 | 241 | 0.200 |
Why?
|
| Spermatic Cord Torsion | 1 | 2021 | 2 | 0.200 |
Why?
|
| Organophosphorus Compounds | 1 | 2022 | 37 | 0.200 |
Why?
|
| Calcium Channels, T-Type | 1 | 2021 | 3 | 0.200 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2022 | 63 | 0.200 |
Why?
|
| Annexin A1 | 1 | 2021 | 3 | 0.200 |
Why?
|
| Furin | 1 | 2021 | 6 | 0.200 |
Why?
|
| Aspirin | 1 | 2022 | 49 | 0.200 |
Why?
|
| Meningeal Neoplasms | 1 | 2021 | 5 | 0.200 |
Why?
|
| Meningioma | 1 | 2021 | 7 | 0.200 |
Why?
|
| Trypsin | 1 | 2021 | 38 | 0.200 |
Why?
|
| Hyperalgesia | 1 | 2021 | 18 | 0.200 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2022 | 62 | 0.200 |
Why?
|
| Transients and Migrants | 1 | 2021 | 39 | 0.200 |
Why?
|
| Nonlinear Dynamics | 1 | 2021 | 33 | 0.200 |
Why?
|
| Databases, Nucleic Acid | 1 | 2021 | 27 | 0.200 |
Why?
|
| Serum Amyloid P-Component | 1 | 2021 | 20 | 0.200 |
Why?
|
| Nanotubes, Carbon | 1 | 2022 | 79 | 0.200 |
Why?
|
| Serine Endopeptidases | 1 | 2021 | 38 | 0.200 |
Why?
|
| Flavonoids | 1 | 2022 | 87 | 0.190 |
Why?
|
| Hemorrhage | 1 | 2021 | 45 | 0.190 |
Why?
|
| Nitrates | 1 | 2021 | 40 | 0.190 |
Why?
|
| Marijuana Abuse | 1 | 2022 | 91 | 0.190 |
Why?
|
| Metabolome | 1 | 2021 | 53 | 0.190 |
Why?
|
| Models, Psychological | 1 | 2021 | 131 | 0.190 |
Why?
|
| Morphine | 1 | 2021 | 85 | 0.190 |
Why?
|
| Gene Frequency | 1 | 2021 | 195 | 0.190 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 97 | 0.190 |
Why?
|
| Opioid-Related Disorders | 1 | 2023 | 125 | 0.190 |
Why?
|
| Immunotherapy | 1 | 2021 | 95 | 0.180 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2021 | 168 | 0.180 |
Why?
|
| Models, Neurological | 1 | 2021 | 128 | 0.180 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 149 | 0.180 |
Why?
|
| Endometrial Neoplasms | 1 | 2021 | 66 | 0.180 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 111 | 0.180 |
Why?
|
| Alleles | 1 | 2021 | 321 | 0.180 |
Why?
|
| Disasters | 1 | 2021 | 65 | 0.180 |
Why?
|
| Insulin Resistance | 1 | 2022 | 184 | 0.180 |
Why?
|
| Flow Cytometry | 1 | 2021 | 399 | 0.180 |
Why?
|
| Obesity | 3 | 2023 | 1067 | 0.180 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 312 | 0.180 |
Why?
|
| Dietary Supplements | 1 | 2022 | 208 | 0.180 |
Why?
|
| Calcium | 1 | 2023 | 480 | 0.180 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2021 | 149 | 0.170 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 213 | 0.170 |
Why?
|
| Software | 1 | 2021 | 217 | 0.170 |
Why?
|
| Pain | 1 | 2022 | 251 | 0.170 |
Why?
|
| Signal Transduction | 3 | 2023 | 1908 | 0.170 |
Why?
|
| RNA, Messenger | 1 | 2024 | 1207 | 0.170 |
Why?
|
| Oxidative Stress | 2 | 2023 | 938 | 0.170 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 935 | 0.170 |
Why?
|
| Female | 9 | 2024 | 20969 | 0.170 |
Why?
|
| Nanoparticles | 1 | 2022 | 318 | 0.150 |
Why?
|
| Membrane Proteins | 1 | 2021 | 517 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 628 | 0.150 |
Why?
|
| Cytokines | 1 | 2021 | 602 | 0.150 |
Why?
|
| Hypertension | 1 | 2023 | 796 | 0.130 |
Why?
|
| Child | 4 | 2024 | 3131 | 0.130 |
Why?
|
| Risk Factors | 1 | 2023 | 3562 | 0.120 |
Why?
|
| Antibodies | 2 | 2024 | 141 | 0.110 |
Why?
|
| Peptide Hydrolases | 2 | 2023 | 40 | 0.110 |
Why?
|
| Chromatography, Liquid | 2 | 2023 | 142 | 0.100 |
Why?
|
| Explosions | 2 | 2022 | 4 | 0.100 |
Why?
|
| Rats, Wistar | 2 | 2023 | 233 | 0.100 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2023 | 182 | 0.100 |
Why?
|
| Adipose Tissue | 2 | 2023 | 177 | 0.100 |
Why?
|
| Drug Discovery | 2 | 2023 | 82 | 0.100 |
Why?
|
| Phosphorylation | 2 | 2024 | 928 | 0.100 |
Why?
|
| Apoptosis | 3 | 2023 | 1398 | 0.090 |
Why?
|
| Mass Spectrometry | 2 | 2021 | 260 | 0.090 |
Why?
|
| Prognosis | 2 | 2023 | 739 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2024 | 1492 | 0.090 |
Why?
|
| Peptides | 2 | 2023 | 320 | 0.090 |
Why?
|
| Young Adult | 3 | 2024 | 4268 | 0.080 |
Why?
|
| Immunohistochemistry | 2 | 2021 | 893 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2023 | 1378 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2024 | 2026 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 2231 | 0.070 |
Why?
|
| Middle Aged | 3 | 2024 | 10129 | 0.060 |
Why?
|
| Diffuse Axonal Injury | 1 | 2024 | 1 | 0.060 |
Why?
|
| Glasgow Outcome Scale | 1 | 2024 | 6 | 0.060 |
Why?
|
| SELEX Aptamer Technique | 1 | 2024 | 5 | 0.060 |
Why?
|
| Okadaic Acid | 1 | 2024 | 15 | 0.060 |
Why?
|
| DNA Polymerase I | 1 | 2023 | 4 | 0.060 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2023 | 6 | 0.060 |
Why?
|
| Serum | 1 | 2023 | 15 | 0.060 |
Why?
|
| Nucleotidyltransferases | 1 | 2023 | 11 | 0.060 |
Why?
|
| Fallopian Tubes | 1 | 2023 | 17 | 0.060 |
Why?
|
| Cinnamates | 1 | 2023 | 6 | 0.060 |
Why?
|
| Arvicolinae | 1 | 2023 | 20 | 0.060 |
Why?
|
| Basement Membrane | 1 | 2023 | 28 | 0.060 |
Why?
|
| ROC Curve | 1 | 2024 | 138 | 0.060 |
Why?
|
| Diazepam | 1 | 2023 | 12 | 0.060 |
Why?
|
| Cameroon | 1 | 2023 | 38 | 0.060 |
Why?
|
| Bicycling | 1 | 2023 | 17 | 0.060 |
Why?
|
| Excipients | 1 | 2023 | 22 | 0.060 |
Why?
|
| Adult | 3 | 2024 | 11712 | 0.060 |
Why?
|
| Glycosylation | 1 | 2023 | 100 | 0.060 |
Why?
|
| Critical Care | 1 | 2023 | 41 | 0.060 |
Why?
|
| 3' Untranslated Regions | 1 | 2023 | 74 | 0.060 |
Why?
|
| Myelin Sheath | 1 | 2023 | 48 | 0.060 |
Why?
|
| Furans | 1 | 2023 | 38 | 0.060 |
Why?
|
| Rare Diseases | 1 | 2022 | 13 | 0.060 |
Why?
|
| Neurogenesis | 1 | 2023 | 58 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2023 | 106 | 0.050 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2023 | 47 | 0.050 |
Why?
|
| Actigraphy | 1 | 2022 | 15 | 0.050 |
Why?
|
| Caspase 6 | 1 | 2022 | 5 | 0.050 |
Why?
|
| Iran | 1 | 2023 | 190 | 0.050 |
Why?
|
| Intermediate Filaments | 1 | 2022 | 19 | 0.050 |
Why?
|
| Ligands | 1 | 2024 | 349 | 0.050 |
Why?
|
| Naltrexone | 1 | 2022 | 38 | 0.050 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2023 | 73 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2022 | 59 | 0.050 |
Why?
|
| Nanomedicine | 1 | 2022 | 35 | 0.050 |
Why?
|
| Cyclic AMP | 1 | 2023 | 131 | 0.050 |
Why?
|
| Caspase 3 | 1 | 2023 | 207 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2023 | 90 | 0.050 |
Why?
|
| Calpain | 1 | 2022 | 35 | 0.050 |
Why?
|
| Extracellular Matrix | 1 | 2023 | 115 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2022 | 89 | 0.050 |
Why?
|
| Review Literature as Topic | 1 | 2021 | 8 | 0.050 |
Why?
|
| Inhalation Exposure | 1 | 2022 | 43 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 161 | 0.050 |
Why?
|
| Scrotum | 1 | 2021 | 4 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 237 | 0.050 |
Why?
|
| Posterior Horn Cells | 1 | 2021 | 3 | 0.050 |
Why?
|
| Mibefradil | 1 | 2021 | 2 | 0.050 |
Why?
|
| Europe | 1 | 2021 | 101 | 0.050 |
Why?
|
| Blood-Brain Barrier | 1 | 2023 | 162 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2022 | 153 | 0.050 |
Why?
|
| Amiloride | 1 | 2021 | 18 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2021 | 7 | 0.050 |
Why?
|
| Injections, Intraperitoneal | 1 | 2021 | 60 | 0.050 |
Why?
|
| Pain Threshold | 1 | 2021 | 28 | 0.050 |
Why?
|
| Biological Assay | 1 | 2021 | 59 | 0.050 |
Why?
|
| Adolescent | 2 | 2023 | 5363 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2023 | 431 | 0.050 |
Why?
|
| Lymph Node Excision | 1 | 2021 | 22 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2023 | 213 | 0.050 |
Why?
|
| Sweat | 1 | 2021 | 18 | 0.050 |
Why?
|
| Lymphatic Metastasis | 1 | 2021 | 65 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2021 | 112 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2023 | 237 | 0.050 |
Why?
|
| Receptors, Opioid, mu | 1 | 2021 | 55 | 0.050 |
Why?
|
| Aged | 2 | 2024 | 6741 | 0.050 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2021 | 103 | 0.050 |
Why?
|
| Carcinogens | 1 | 2022 | 124 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2024 | 894 | 0.050 |
Why?
|
| Polysaccharides | 1 | 2021 | 58 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2023 | 222 | 0.050 |
Why?
|
| Metabolomics | 1 | 2021 | 81 | 0.050 |
Why?
|
| Dopamine | 1 | 2022 | 245 | 0.050 |
Why?
|
| Biopsy | 1 | 2021 | 164 | 0.050 |
Why?
|
| Mammals | 1 | 2021 | 105 | 0.050 |
Why?
|
| Infant | 1 | 2024 | 1046 | 0.050 |
Why?
|
| Pain Measurement | 1 | 2021 | 171 | 0.050 |
Why?
|
| Protein Conformation | 1 | 2021 | 389 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2021 | 325 | 0.050 |
Why?
|
| Electroencephalography | 1 | 2021 | 116 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 204 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2023 | 339 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 661 | 0.040 |
Why?
|
| Hippocampus | 1 | 2023 | 561 | 0.040 |
Why?
|
| Research Design | 1 | 2021 | 313 | 0.040 |
Why?
|
| Mitochondria | 1 | 2023 | 487 | 0.040 |
Why?
|
| Computational Biology | 1 | 2021 | 293 | 0.040 |
Why?
|
| Lung | 1 | 2022 | 446 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2022 | 1369 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2021 | 1180 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1039 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2023 | 681 | 0.040 |
Why?
|
| Age Factors | 1 | 2021 | 1033 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2023 | 1198 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 664 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 807 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2022 | 2379 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 2721 | 0.030 |
Why?
|
| Neoplasms | 1 | 2022 | 1103 | 0.020 |
Why?
|
| United States | 1 | 2021 | 4223 | 0.020 |
Why?
|